0001193125-14-032968.txt : 20140306 0001193125-14-032968.hdr.sgml : 20140306 20140203160423 ACCESSION NUMBER: 0001193125-14-032968 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20140203 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Eleven Biotherapeutics, Inc. CENTRAL INDEX KEY: 0001485003 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 252025616 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 400 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-871-9911 MAIL ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 400 CITY: CAMBRIDGE STATE: MA ZIP: 02142 CORRESP 1 filename1.htm CORRESP

ELEVEN BIOTHERAPEUTICS, INC.

215 FIRST STREET, SUITE 400

CAMBRIDGE, MA 02142

 

February 3, 2014

 

Via EDGAR

 

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

 

Re:   Eleven Biotherapeutics, Inc.
       Registration Statement on Form S-1
       File No. 333-193131
       Request for Acceleration

 

Ladies and Gentlemen:

 

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Eleven Biotherapeutics, Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-1 (File No. 333-193131), as amended (the “Registration Statement”), so that it may become effective at 4:00 p.m. Eastern time on February 5, 2014, or as soon thereafter as practicable.

 

The Registrant hereby acknowledges that:

 

(a)   should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement;

 

(b)   the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and

 

(c)   the Registrant may not assert staff comments and the declaration of effectiveness of the Registration Statement as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

 

 

[The remainder of this page is intentionally left blank.]

Very truly yours,

 

Eleven Biotherapeutics, Inc.

By:   /s/ Abbie C. Celniker

Name:

Title:

  

Abbie C. Celniker, Ph.D.

President and Chief Executive Officer